-
市场
-
产品
-
资讯
-
Moo社区
-
课堂
-
查看更多
-
功能介绍
-
费用费用透明,无最低余额限制
投资选择、功能介绍、费用相关信息由Moomoo Financial Inc.提供
- English
- 中文繁體
- 中文简体
- 深色
- 浅色
Avalo to Present at the H.C. Wainwright Global Investment Conference
Avalo to Present at the H.C. Wainwright Global Investment Conference
WAYNE, Pa. and ROCKVILLE, Md., Sept. 01, 2022 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (Nasdaq: AVTX) announced today that Garry A. Neil, M.D., President and Chief Executive Officer, will present virtually at the H.C. Wainwright Global Investment Conference being held September 12-14, 2022.
The pre-recorded formal presentation will be made available on Monday, September 12, 2022 at 7:00 AM ET. A webcast of the pre-recorded presentation can be accessed under the "News/Events" page in the Investors section of the Company's website, .
About Avalo Therapeutics
Avalo Therapeutics is a clinical stage biotechnology company focused on the treatment of immune dysregulation by developing therapies that target the LIGHT-signaling network.
LIGHT (Lymphotoxin-like, exhibits Inducible expression, and competes with HSV Glycoprotein D for Herpesvirus Entry Mediator (HVEM), a receptor expressed by T lymphocytes; also referred to as TNFSF14) is an immunoregulatory cytokine. LIGHT and its signaling receptors, HVEM (TNFRSF14), and lymphotoxin β receptor, form an immune regulatory network with two co-receptors of herpesvirus entry mediator, checkpoint inhibitor B and T Lymphocyte Attenuator (BTLA), and CD160 (the LIGHT-signaling network). Accumulating evidence points to the dysregulation of the LIGHT-signaling network as a disease-driving mechanism in autoimmune and inflammatory reactions in barrier organs. Therefore, we believe reducing LIGHT can moderate immune dysregulation in many acute and chronic inflammatory disorders.
For more information about Avalo, please visit .
Forward-Looking Statements
This press release may include forward-looking statements made pursuant to the Private Securities Litigation Reform Act of 1995. Forward-looking statements are statements that are not historical facts. Such forward-looking statements are subject to significant risks and uncertainties that are subject to change based on various factors (many of which are beyond Avalo's control), which could cause actual results to differ from the forward-looking statements. Such statements may include, without limitation, statements with respect to Avalo's plans, objectives, projections, expectations and intentions and other statements identified by words such as "projects," "may," "might," "will," "could," "would," "should," "continue," "seeks," "aims," "predicts," "believes," "expects," "anticipates," "estimates," "intends," "plans," "potential," or similar expressions (including their use in the negative), or by discussions of future matters such as: the future financial and operational outlook; the development of product candidates or products; timing and success of trial results and regulatory review; potential attributes and benefits of product candidates; and other statements that are not historical. These statements are based upon the current beliefs and expectations of Avalo's management but are subject to significant risks and uncertainties, including: Avalo's cash position and the potential need for it to raise additional capital; drug development costs, timing and other risks, including reliance on investigators and enrollment of patients in clinical trials, which might be slowed by the COVID-19 pandemic; reliance on key personnel, including as a result of recent management and Board changes; regulatory risks; general economic and market risks and uncertainties, including those caused by the COVID-19 pandemic and tensions in Ukraine; and those other risks detailed in Avalo's filings with the SEC. Actual results may differ from those set forth in the forward-looking statements. Except as required by applicable law, Avalo expressly disclaims any obligations or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in Avalo's expectations with respect thereto or any change in events, conditions or circumstances on which any statement is based.
For investor inquiries
Christopher Sullivan, CFO
Avalo Therapeutics, Inc.
csullivan@avalotx.com
410-803-6793
or
Chris Brinzey
ICR Westwicke
Chris.brinzey@westwicke.com
339-970-2843
WAYNE, Pa. and ROCKVILLE, Md., Sept. 01, 2022 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (Nasdaq: AVTX) announced today that Garry A. Neil, M.D., President and Chief Executive Officer, will present virtually at the H.C. Wainwright Global Investment Conference being held September 12-14, 2022.
宾夕法尼亚州韦恩马里兰州罗克维尔,9月环球通讯社2022年01日电阿瓦洛治疗公司(纳斯达克代码:AVTX)今天宣布,加里·尼尔医学博士、总裁兼首席执行官将出席2022年9月12日至14日举行的H.C.温赖特全球投资大会。
The pre-recorded formal presentation will be made available on Monday, September 12, 2022 at 7:00 AM ET. A webcast of the pre-recorded presentation can be accessed under the "News/Events" page in the Investors section of the Company's website, .
预先录制的正式演示文稿将于2022年9月12日(星期一)美国东部时间上午7:00提供。预先录制的演示文稿的网络直播可在公司网站投资者部分的“新闻/事件”页面上观看。
About Avalo Therapeutics
关于Avalo Treateutics
Avalo Therapeutics is a clinical stage biotechnology company focused on the treatment of immune dysregulation by developing therapies that target the LIGHT-signaling network.
Avalo Treateutics是一家临床阶段的生物技术公司,专注于通过开发针对光信号网络的疗法来治疗免疫失调。
LIGHT (Lymphotoxin-like, exhibits Inducible expression, and competes with HSV Glycoprotein D for Herpesvirus Entry Mediator (HVEM), a receptor expressed by T lymphocytes; also referred to as TNFSF14) is an immunoregulatory cytokine. LIGHT and its signaling receptors, HVEM (TNFRSF14), and lymphotoxin β receptor, form an immune regulatory network with two co-receptors of herpesvirus entry mediator, checkpoint inhibitor B and T Lymphocyte Attenuator (BTLA), and CD160 (the LIGHT-signaling network). Accumulating evidence points to the dysregulation of the LIGHT-signaling network as a disease-driving mechanism in autoimmune and inflammatory reactions in barrier organs. Therefore, we believe reducing LIGHT can moderate immune dysregulation in many acute and chronic inflammatory disorders.
灯光(L类粘菌素,展品I可诱导表达,并与HSV竞争G赖氨酸蛋白DHERPSE病毒进入介体(HVEM),一种由T淋巴细胞(又称TNFSF14)是一种免疫调节细胞因子。LIGHT及其信号受体hVEM(TNFRSF14)和淋巴毒素β受体与疱疹病毒进入介导物、检查点抑制因子B和T淋巴细胞衰减剂(BTLA)以及LIGH信号网络CD160形成免疫调节网络。越来越多的证据表明,光信号网络的失调是屏障器官自身免疫和炎症反应中的一种疾病驱动机制。因此,我们认为减少光照可以缓解许多急、慢性炎症性疾病的免疫失调。
For more information about Avalo, please visit .
有关Avalo的更多信息,请访问。
Forward-Looking Statements
前瞻性陈述
This press release may include forward-looking statements made pursuant to the Private Securities Litigation Reform Act of 1995. Forward-looking statements are statements that are not historical facts. Such forward-looking statements are subject to significant risks and uncertainties that are subject to change based on various factors (many of which are beyond Avalo's control), which could cause actual results to differ from the forward-looking statements. Such statements may include, without limitation, statements with respect to Avalo's plans, objectives, projections, expectations and intentions and other statements identified by words such as "projects," "may," "might," "will," "could," "would," "should," "continue," "seeks," "aims," "predicts," "believes," "expects," "anticipates," "estimates," "intends," "plans," "potential," or similar expressions (including their use in the negative), or by discussions of future matters such as: the future financial and operational outlook; the development of product candidates or products; timing and success of trial results and regulatory review; potential attributes and benefits of product candidates; and other statements that are not historical. These statements are based upon the current beliefs and expectations of Avalo's management but are subject to significant risks and uncertainties, including: Avalo's cash position and the potential need for it to raise additional capital; drug development costs, timing and other risks, including reliance on investigators and enrollment of patients in clinical trials, which might be slowed by the COVID-19 pandemic; reliance on key personnel, including as a result of recent management and Board changes; regulatory risks; general economic and market risks and uncertainties, including those caused by the COVID-19 pandemic and tensions in Ukraine; and those other risks detailed in Avalo's filings with the SEC. Actual results may differ from those set forth in the forward-looking statements. Except as required by applicable law, Avalo expressly disclaims any obligations or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in Avalo's expectations with respect thereto or any change in events, conditions or circumstances on which any statement is based.
本新闻稿可能包括根据1995年《私人证券诉讼改革法》作出的前瞻性陈述。前瞻性陈述是指非历史事实的陈述。此类前瞻性陈述会受到重大风险和不确定性的影响,这些风险和不确定性可能会因各种因素而发生变化(其中许多因素不在Avalo的控制范围之内),这可能会导致实际结果与前瞻性陈述不同。此类陈述可包括但不限于,关于Avalo的计划、目标、预测、期望和意图的陈述,以及由诸如“项目”、“可能”、“可能”、“将”、“应该”、“继续”、“寻求”、“目标”、“预测”、“相信”、“预期”、“预期”、“估计”、“打算”等词语标识的其他陈述。“计划”、“潜在的”或类似的表达(包括它们在否定中的用法),或通过讨论未来的事项,如:未来的财务和经营前景;候选产品或产品的开发;试验结果和监管审查的时机和成功;候选产品的潜在属性和好处;以及其他非历史性的陈述。这些陈述基于阿瓦洛公司管理层目前的信念和预期,但也存在重大风险和不确定性,包括:阿瓦洛公司的现金状况及其筹集额外资本的潜在需要;药物开发成本、时间和其他风险,包括对研究人员的依赖和临床试验患者的招募,这可能因新冠肺炎疫情而放缓;对关键人员的依赖,包括最近管理层和董事会变动的结果;监管风险;总体经济和市场风险以及不确定因素。, 包括新冠肺炎疫情和乌克兰紧张局势造成的风险,以及阿瓦洛提交给美国证券交易委员会的文件中详细介绍的其他风险。实际结果可能与前瞻性陈述中陈述的结果不同。除适用法律另有要求外,Avalo明确表示不承担任何义务或承诺公开发布本文中包含的任何前瞻性陈述的任何更新或修订,以反映Avalo对此的预期的任何变化,或任何陈述所基于的事件、条件或情况的任何变化。
For investor inquiries
供投资者查询
Christopher Sullivan, CFO
Avalo Therapeutics, Inc.
csullivan@avalotx.com
410-803-6793
首席财务官克里斯托弗·沙利文
Avalo治疗公司
邮箱:csullivan@avalotx.com
410-803-6793
or
或
Chris Brinzey
ICR Westwicke
Chris.brinzey@westwicke.com
339-970-2843
克里斯·布林齐
ICR Westwicke
邮箱:Chris.brinzey@westwicke.com
339-970-2843
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国,moomoo上的投资产品和服务由Moomoo Financial Inc.提供,一家受美国证券交易委员会(SEC)监管的持牌主体。 Moomoo Financial Inc.是金融业监管局(FINRA)和证券投资者保护公司(SIPC)的成员。
在新加坡,moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供,该公司受新加坡金融管理局(MAS)监管(牌照号码︰CMS101000) ,持有资本市场服务牌照 (CMS) ,持有财务顾问豁免(Exempt Financial Adviser)资质。本内容未经新加坡金融管理局的审查。
在澳大利亚,moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供,该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构(AFSL No. 224663)。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件,这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大,通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供,并受加拿大投资监管机构(CIRO)监管。
在马来西亚,moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供,该公司受马来西亚证券监督委员会(SC)监管(牌照号码︰eCMSL/A0397/2024) ,持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
风险及免责提示
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国,moomoo上的投资产品和服务由Moomoo Financial Inc.提供,一家受美国证券交易委员会(SEC)监管的持牌主体。 Moomoo Financial Inc.是金融业监管局(FINRA)和证券投资者保护公司(SIPC)的成员。
在新加坡,moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供,该公司受新加坡金融管理局(MAS)监管(牌照号码︰CMS101000) ,持有资本市场服务牌照 (CMS) ,持有财务顾问豁免(Exempt Financial Adviser)资质。本内容未经新加坡金融管理局的审查。
在澳大利亚,moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供,该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构(AFSL No. 224663)。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件,这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大,通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供,并受加拿大投资监管机构(CIRO)监管。
在马来西亚,moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供,该公司受马来西亚证券监督委员会(SC)监管(牌照号码︰eCMSL/A0397/2024) ,持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用浏览器的分享功能,分享给你的好友吧